Summit Therapeutics Inc. Common Stock (SMMT)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
$0.64 (-3.43%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Summit Therapeutics Inc. Common Stock (SMMT)
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Key Insights

Critical company metrics and information
  • Share Price

    $18.01
  • Market Cap

    $13.28 Billion
  • Total Outstanding Shares

    737.45 Million Shares
  • Total Employees

    105
  • Dividend

    No dividend
  • IPO Date

    March 5, 2015
  • SIC Description

    Pharmaceutical Preparations
  • Homepage

    https://www.smmttx.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Operating Activities$-112.89 Million
Net Cash Flow$69.94 Million
Net Cash Flow From Financing Activities, Continuing$411.09 Million
Net Cash Flow From Operating Activities, Continuing$-112.89 Million
Net Cash Flow From Financing Activities$411.09 Million
Net Cash Flow From Investing Activities$-228.25 Million
Net Cash Flow From Investing Activities, Continuing$-228.25 Million
Net Cash Flow, Continuing$69.94 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Income/Loss$-196.68 Million
Operating Income/Loss$-196.59 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Income/Loss From Continuing Operations Before Tax$-196.68 Million
Revenues$287,000.00
Basic Earnings Per Share$-0.23
Benefits Costs and Expenses$196.97 Million
Costs And Expenses$196.88 Million
Net Income/Loss Attributable To Parent$-196.68 Million
Preferred Stock Dividends And Other Adjustments$0.00
Income/Loss From Continuing Operations After Tax$-196.68 Million
Diluted Average Shares$739.45 Million
Diluted Earnings Per Share$-0.23
Nonoperating Income/Loss$-85,000.00
Basic Average Shares$739.45 Million
Net Income/Loss Available To Common Stockholders, Basic$-196.68 Million
Operating Expenses$196.88 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Equity$437.92 Million
Other Current Liabilities$47.80 Million
Current Liabilities$59.01 Million
Fixed Assets$265,000.00
Other Non-current Assets$12.30 Million
Liabilities And Equity$502.85 Million
Current Assets$490.29 Million
Accounts Payable$3.25 Million
Noncurrent Assets$12.56 Million
Equity Attributable To Parent$437.92 Million
Equity Attributable To Noncontrolling Interest$0.00
Assets$502.85 Million
Noncurrent Liabilities$5.92 Million
Liabilities$64.93 Million
Wages$7.96 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.